May 13, 2008. PRESS RELEASE: AlphaSniffer changes the name to BiOptix.

Contact: Misha Plam,
President/CEO,
BiOptix LLC
(303) 641-3669
m.plam@comcast.net
http://www.BiOptix.com

Boulder, Colorado, March 13, 2008.

AlphaSniffer LLC, a privately held company commercializing new technologies for rapid, sensitive, label-free detection of biomarkers, announced today that a majority of shareholders and the Board of Directors have approved a name change from AlphaSniffer to BiOptix.

The name change to BiOptix accurately reflects both the company’s present technology platform and its shifted market focus.

AlphaSniffer, established in 2003, is developing a proprietary technology for real-time, sensitive, label-free detection of medically and commercially important molecules such as DNA, proteins, toxins, contaminants and other compounds. Applications using this broad technology platform include real-time detection instruments for markets such as medical research, personalized medicine and diagnostics, pharmaceutical process control, defense and homeland security, and numerous other industrial demands. The core technology, known as SPR-CPI, was invented at AlphaSniffer by Dr. John Hall, 2005 Physics Nobel Prize Laureate, Slava Petropavlovskikh, and Dr. Oyvind Nilsen. Having established proof of principle through development of several functional prototypes and surface chemistries, the company is now extending the capabilities of its instruments by engineering a medium density array system.